Introduction
============

Worldwide, primary liver cancer (PLC) is the second leading cause of cancer-associated mortality in poorly developed countries and the sixth in more developed countries ([@b1-mmr-18-05-4446]). Of the \~782,500 new annual cases of PLC, China accounts for \>50% of the associated incidence ([@b2-mmr-18-05-4446]). In 2015, PLC was the fourth most common type of cancer and the third most common cause of cancer-associated mortality in China ([@b3-mmr-18-05-4446]). The majority of PLC cases occurring worldwide are cases of hepatocellular carcinoma (HCC) ([@b1-mmr-18-05-4446]). Many risk factors can induce the development of HCC, including chronic hepatitis B virus or hepatitis C virus infections, chronic alcoholic cirrhosis and high doses of aflatoxin B1 ([@b4-mmr-18-05-4446]). Although a number of studies have identified a few of the molecular alterations associated with the pathogenesis of HCC, the main mechanism underlying HCC is still unclear.

Previous studies have demonstrated that epigenetic alterations are one of the many early events that occur during tumorigenesis ([@b5-mmr-18-05-4446],[@b6-mmr-18-05-4446]). DNA methylation is the main epigenetic feature in regulating gene transcriptional regulation and preserving genome stability; however, aberrant DNA methylation can lead to the inactivation of tumor suppressor genes or activation of oncogenes, which eventually induces the development of many types of cancer ([@b7-mmr-18-05-4446],[@b8-mmr-18-05-4446]). A number of studies have also reported alterations in one or several genes at one time; the abnormal methylation of genes, including Ras association domain family member 1 ([@b9-mmr-18-05-4446]), p16, postmeiotic segregation increased 2, MutL homolog 1, MutS homolog 2 ([@b10-mmr-18-05-4446]), Adenomatosis polyposis coli ([@b11-mmr-18-05-4446]) and glutathione S-transferase Pi 1 ([@b12-mmr-18-05-4446],[@b13-mmr-18-05-4446]), has also been associated with HCC. Shen *et al* ([@b14-mmr-18-05-4446]) used Illumina Infinium HumanMethylation 27K arrays to analyze 27,578 CpG sites covering 14,495 genes in paired HCC tumor and adjacent non-tumor tissues. The Illumina Infinium HumanMethylation 450K BeadChip represents a significant improvement in the detection of CpG sites (482,421 CpG and 3,091 non-CpG sites), covers 99% of RefSeq genes with multiple sites in annotated promoters (1,500 or 200 bp upstream of the transcription start site), 5′-untranslated regions (UTRs), first exons, gene body, and 3′-UTRs ([@b15-mmr-18-05-4446]). Previously, aberrant DNA hypermethylation of CpG islands was reported to induce the inactivation of tumor suppressor genes ([@b16-mmr-18-05-4446]), which was thought to contribute to tumorigenesis ([@b17-mmr-18-05-4446]). Recently, previous studies have revealed that cancer-associated aberrant DNA methylation not only occurs within CpG islands but may also be detected within CpG shores or CpG shelves ([@b18-mmr-18-05-4446]--[@b20-mmr-18-05-4446]).

To the best of our knowledge, no research analyzing the genome-wide DNA methylation status within a HCC cell line using the Illumina Infinium HumanMethylation 450K BeadChip has been conducted. Therefore, in the present study, the Illumina 450K Methylation BeadChip was employed to screen promoter DNA methylation and the expression profiles of methylated genes in a human hepatocellular carcinoma cell line (Huh7 cells) and in a human normal liver cell line (L02 cells). The results may aid the characterization of differentially methylated CpG sites, regions and genes associated with the pathogenesis of HCC, thereby improving our current understanding of the methylation mechanisms underlying the development and progression of HCC.

Materials and methods
=====================

### Cell culture

The human HCC cell line, Huh7 and the human normal liver cell line, L02, were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). Huh7 cells were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), while L02 cells were maintained in RPMI-1640 (Invitrogen; Thermo Fisher Scientific, Inc.). The cell lines were supplemented with 100 U/ml penicillin and 100 g/ml streptomycin in the presence of 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.) and incubated in a humidified atmosphere containing 5% CO~2~ at 37°C.

### DNA preparation and Illumina Infinium HumanMethylation 450K BeadChip assay

DNA was extracted from the two cell lines (Huh7 and L02) using a QIAamp DNA Micro kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer\'s protocol. Bisulfite modification of 1 µg DNA was conducted using an EZ DNA Methylation kit (Zymo Research Corp., Irvine, CA, USA) according to the manufacturer\'s protocol. The Illumina Infinium HumanMethylation 450K BeadChip assay was performed according to Illumina\'s standard protocol (Illumina, Inc., San Diego, CA, USA). Experiments with Huh7 and L02 cells were performed in triplicate to avoid false positive and false negative results.

### Statistical analysis

The methylation data were processed with the Methylation Module of GenomeStudio software (Methylation v1.9; Illumina, Inc.). The methylation levels of the CpG sites were calculated as β-values: β=intensity of the methylated allele (M)/\[intensity of the unmethylated allele (U) + M + 100\] ([@b15-mmr-18-05-4446]). A t-test, in addition to analysis of variance with Bonferroni correction for multiple comparisons was used to compare differentially methylated CpG sites between Huh7 and L02 cells. The differentially methylated CpG sites were defined as sites with Adjusted P-values of ≤0.05 and \|β-Difference\|≥0.2. Methylation measures with a detection P\>0.05 and CpG coverage \<95% were excluded ([@b14-mmr-18-05-4446]). For the selection of candidate CpG sites that had significant differences between Huh7 and L02 cell methylation levels, the following additional filtering criteria were applied: i) Adjusted P≤0.05, which corresponds to a raw P-value of ≤1.06×10^−7^; ii) for significantly hypermethylated CpG sites, the \|β-Difference\| in the methylation levels between Huh7 and L02 cells was \>20%, and the mean methylation level for L02 was \<25%; and iii) for significantly hypomethylated CpG sites, the methylation level \|β-Difference\| between L02 and Huh7 cells was \>20%, and the mean methylation level for Huh7 cells was \<25% ([@b14-mmr-18-05-4446]).

### Functional annotation of differentially methylated genes

The genes for which the CpG sites corresponded with differential methylation levels were determined using Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway ([www.genome.jp/kegg/](www.genome.jp/kegg/)) and Gene Ontology (GO; [www.geneontology.org/](www.geneontology.org/)) databases to analyze the pathway and enrichment information of these genes.

Results
=======

### Global DNA methylation in Huh7 and LO2 cells

Following a t-test with Bonferroni correction for multiple comparisons, 102,254 differentially methylated CpG sites (covering 26,511 genes) were detected between Huh7 and L02 cells. Within these CpG sites, 62,702 (61.3%) sites were hypermethylated (covering 12,665 genes), and 39,552 (38.7%) sites were hypomethylated (covering 13,846 genes). The results suggested that aberrant DNA methylation may a very common event in Huh7 cells, and alterations in hypermethylation were more frequently observed than hypomethylation. [Figs. 1](#f1-mmr-18-05-4446){ref-type="fig"} and [2](#f2-mmr-18-05-4446){ref-type="fig"} present hierarchical cluster analysis of the differentially methylated CpG sites and genes that distinguish Huh7 from L02 cells.

In addition, the results revealed that there were 41,178 (40.3%) CpG sites located in CpG island regions, 21,150 (20.7%) CpG sites were within CpG shores, 9,030 (8.8%) CpG sites were in shelves, and 30,896 (30.2%) CpG sites were in open sea ([Table I](#tI-mmr-18-05-4446){ref-type="table"}). Furthermore, the results also demonstrated that within different regions, the distribution of hypo- or hypermethylated CpG sites differed: In CpG island regions, 19,462 (47.3%) CpG sites were hypermethylated and 21,716 (52.7%) CpG sites were hypomethylated. In CpG shore regions, 13,729 (64.9%) CpG sites were hypermethylated and 7,421 (35.1%) CpG sites were hypomethylated. In shelf regions, 7,340 (81.3%) CpG sites were hypermethylated and 1,690 (18.7%) CpG sites were hypomethylated.

Frequency distribution of differentially methylated CpG sites between Huh7 and L02 cells. In the results of the present study, 35,937 (57.3%) hypermethylated CpG sites and 15,587 (39.4%) hypomethylated CpG sites were observed to have an \|β-Difference\|≥50%. A total of 18,529 (29.5%) of hypermethylated CpG sites and 14,177 (35.9%) hypomethylated CpG sites had an \|β-Difference\|≥30% but \<50%. A total of 8,236 (13.1%) hypermethylated CpG sites and 9,788 (24.7%) of hypomethylated CpG sites had an \|β-Difference\|\<30% but ≥20% ([Table II](#tII-mmr-18-05-4446){ref-type="table"}). Collectively, these results revealed that DNA aberrant hypermethylation in Huh7 cells was more frequent than in L02 cells, which may serve a potential role in genomic instability.

### Significant differentially methylated CpG sites and genes

To reduce the potential impact of an extreme β value on methylation differences, the present study applied stringent criteria to select potentially biologically important CpG sites ([@b14-mmr-18-05-4446]). A total of 5,285 significantly hypermethylated CpG sites (covering 3,222 genes) and 2,659 significantly hypomethylated CpG sites (covering 2,204 genes) were observed. For the significantly hypermethylated CpG sites, there were 1,544 sites in CpG islands, 1,137 sites in CpG shores, 655 sites within CpG shelves and 1,949 sites in open sea regions. By contrast, for the significantly hypomethylated CpG sites, there were 1,201 sites in CpG islands, 632 sites in CpG shores, 133 sites in CpG shelves and 693 sites in open sea regions ([Table III](#tIII-mmr-18-05-4446){ref-type="table"}). The top 20 differentially hypermethylated and hypomethylated sites and genes are presented in the [Tables IV](#tIV-mmr-18-05-4446){ref-type="table"} and [V](#tV-mmr-18-05-4446){ref-type="table"}.

### Significant differentially methylated regions (DMRs)

The results of the present study revealed that 390 significantly hypermethylated CpG sites (covering 287 genes) and 208 significantly hypomethylated CpG sites (covering 203 genes) were in DMRs. For the significantly hypermethylated CpG sites, 64 sites were in cancer-specific (c)-DMRs, 125 sites were in reprogramming-specific (r)-DMRs and 201 sites were in DMRs; for the significantly hypomethylated CpG sites, 30 were located within cDMRs, 74 were located within rDMRs and 104 were located within DMRs ([Table VI](#tVI-mmr-18-05-4446){ref-type="table"}; [Fig. 3](#f3-mmr-18-05-4446){ref-type="fig"}).

### GO enrichment and KEGG pathway analysis

GO enrichment and the KEGG Pathway database were employed to analyze information regarding the differentially methylated genes. The results of GO enrichment revealed that there were 2,107 differentially methylated genes associated with 'biological process', and the most enriched groups included negative regulators of cell proliferation, negative regulators of transcription such as RNA polymerase II promoter, and synaptic transmission. A total of 13,351 differentially methylated genes were associated with 'molecular function', and the most enriched groups included protein binding, DNA binding and metal ion binding. A total of 18,041 differentially methylated genes were associated with 'cellular component', and the most enriched groups included the nucleus, cytoplasm and cytosol ([Fig. 4](#f4-mmr-18-05-4446){ref-type="fig"}). The top 20 significant differentially methylated genes obtained from GO enrichment analysis are listed in [Table VII](#tVII-mmr-18-05-4446){ref-type="table"}.

KEGG Pathway-based analyses revealed that 43 signaling pathways involved 5,195 differentially methylated genes, and these genes were significantly enriched in specific pathways, including the cancer, metabolic, mitogen-activated protein kinase (MAPK), calcium, Wnt, hepatitis C, Erb-B2 receptor tyrosine kinase (ErbB), transforming growth factor (TGF)-β, vascular endothelial growth factor (VEGF), p53 and Notch signaling pathways ([Table VIII](#tVIII-mmr-18-05-4446){ref-type="table"}).

Discussion
==========

DNA methylation is the main epigenetic modification and regulator of gene expression in humans. Aberrant changes in genomic methylation patterns have been observed in many cancer cell lines; these are regarded as the major type of molecular aberration in malignancies ([@b7-mmr-18-05-4446],[@b8-mmr-18-05-4446]). Previous studies have evaluated aberrant DNA methylation in HCC by analyzing tumor tissues and adjacent non-tumor tissues ([@b14-mmr-18-05-4446],[@b21-mmr-18-05-4446]--[@b23-mmr-18-05-4446]). Their main aims were to identify novel potential biomarkers for the diagnosis of HCC or to study the associations between methylation and cirrhosis-associated HCC; the study design and enrolment criteria differed when selecting various patients for study. In addition, variations in ethnicity and the effects of the cutting edge of adjacent non-tumor tissues may lead to differing results observed across the different studies. Although previous studies have indicated a few novel DNA methylation markers that are associated with HCC, specific DNA methylation patterns associated with the progression of HCC and alterations in methylation between HCC and normal liver cells have yet to be identified. In the present study, Illumina Infinium HumanMethylation 450K BeadChip was used to identify global DNA methylation profiles in Huh7 and L02 cells.

In the present study, a total of 102,254 differentially methylated CpG sites were detected across the whole-genome of Huh7 and L02 cells; more hypermethylated CpG sites (62,702; 61.3%) were observed than hypomethylated (39,552; 38.7%) CpG sites. The results indicated that within Huh7 cells, aberrant DNA methylation was a very common event and that hypermethylation of CpG sites occurred more frequently than hypomethylation. In addition, stringent criteria were employed to select the significantly differentially methylated CpG sites, genes and DMRs. Finally, 5,285 (66.5%) significantly hypermethylated and 2,659 (33.5%) hypomethylated CpG sites were identified. It has been reported that, in many types of diseases including cancers, aberrant DNA methylation is a common event, particularly aberrant DNA methylation of CpG islands or within promoter regions, which are associated with tumor suppressor gene inactivation or oncogene activation ([@b16-mmr-18-05-4446]). The results of the present study indicated that within a CpG island, a greater number of significantly hypermethylated CpG sites (1,544) were observed than significantly hypomethylated CpG sites (1,201). This result is consistent with previous HCC genome-wide methylation studies ([@b14-mmr-18-05-4446],[@b24-mmr-18-05-4446]--[@b27-mmr-18-05-4446]). Yates *et al* ([@b18-mmr-18-05-4446]) and Dudziec *et al* ([@b19-mmr-18-05-4446]) demonstrated that aberrant DNA methylation occurs in CpG islands, but can also be detected in the regions adjacent to CpG islands, CpG shores and CpG shelves ([@b15-mmr-18-05-4446]), and may lead to tumorigenesis ([@b20-mmr-18-05-4446],[@b28-mmr-18-05-4446],[@b29-mmr-18-05-4446]). The present study also demonstrated these points; significantly hypermethylated CpG sites in the CpG shores regions were more abundant than significantly hypomethylated CpG sites (1,137 to 632). In addition, in the CpG shelf regions, the significantly hypermethylated CpG sites were more frequent than significantly hypomethylated CpG sites (655 to 133).

DMRs are stretches of DNA in the genome. Varied DNA methylation patterns are seen between different organisms, and adjacent sites or a group of sites in proximity to each other tend to have different methylation patterns between different diseases ([@b30-mmr-18-05-4446]). DMRs are associated with many diseases including several types of cancer ([@b31-mmr-18-05-4446]). There are also many types of DMRs: Tissue-specific DMRs, cDMRs, rDMRs, imprinting-specific DMRs and aging-specific DMRs ([@b20-mmr-18-05-4446]). In the present study, there were 390 differentially hypermethylated CpG sites located within DMRs, 233 (59.7%) were in island regions, 119 (30.5%) were in shore regions, and 15 (3.8%) were in shelf regions. In addition, there were 208 differentially hypomethylated CpG sites located within DMRs, 87 (41.8%) were in CpG island regions, 89 (42.8%) were in shore regions and 6 (2.9%) were in shelf regions. These results indicated that within HCC cells, aberrant DNA methylation may occur within CpG shore regions, which can also cause DNA transcriptional silencing and inactivation of gene function. Hepatocarcinogenesis was also associated with genomic instability and inactivation of gene function; the results of the present study concerning DMRs suggests that aberrant methylation within these sites may be an important epigenetic mechanism associated with hepatocarcinogenesis. These results may provide more information regarding the associations between HCC and aberrant DNA methylation.

Furthermore, the present study listed the top 20 significantly hyper- and hypo-methylated CpG sites, and genes in DMRs within Huh7 cells compared with L02 cells. The top 20 significantly hypermethylated genes, which were high-ranking with notable differences in the absolute value of β-difference, included the following: ERBB4, paired box 6, splat like transcription factor 4, protocadherin (PCDH)-8, NK2 homeobox 6, B-cell lymphoma (BCL)-3, glypican 6, family with sequence similarity 196 member A, dedicator of cytokinesis 1, Meis homeobox 2, Zic family member 4, transcription factor 21, zinc finger and BTB domain containing 32, leucine rich repeat and fibronectin type III domain containing 2, BCL2, PCDH9, DPY30 domain-containing protein 2, zinc finger CCHC-type containing 24, brain-derived neurotrophic factor, cg00057722 and cg08640046. The functional role of these genes in HCC requires further study. The top 20 significant differentially hyper- and hypo-methylated genes from GO enrichment were also listed. These genes, which were located within DMRs, were mainly associated with 'cell differentiation development', 'transcription factor activity', 'sequence-specific DNA binding', 'cellular development process' and 'cell junction'.

Additionally, through GO enrichment analysis, the present study revealed that aberrant DNA methylation in HCC was associated with cell differentiation and proliferation, and through KEGG pathway analysis, 43 signaling pathways associated with HCC were identified, including pathways in cancer, MAPK signaling, Wnt signaling, VEGF signaling and p53 signaling pathways. Previous studies have demonstrated that aberrant DNA hypermethylation can downregulate the expression of cell cycle inhibitors, p16^INK4A^, p53 and factors involved in TGF-β/mothers against decapentaplegic signaling ([@b32-mmr-18-05-4446],[@b33-mmr-18-05-4446]). Thus far, researchers have revealed that the inactivation of Wnt pathway-associated antagonists is linked to the aberrant DNA hypermethylation of some genes ([@b34-mmr-18-05-4446],[@b35-mmr-18-05-4446]). Activation of the ERB receptor and MAPK signaling pathways, as well as the regulation of epigenetic proteins that were previously demonstrated to promote cancer growth and metastasis, have been reported to be possible candidate targets for anticancer treatment in multiple types of cancer, including HCC ([@b32-mmr-18-05-4446],[@b36-mmr-18-05-4446]).

In addition, HCC cells may escape or become tolerant to chemotherapy via various mechanisms, therefore, identifying novel drugs is very important for the future therapy of HCC. The application of inhibitors of DNA methylated drugs in the treatment of cancer has gradually attracted the attention of researchers ([@b37-mmr-18-05-4446]), including 5-azacytidine (5-aza-C), decitabine (5-aza-2′-deoxycytidine, 5-aza-dC), 1-β-D-arabinofuranosyl-5-azacytosine, dihydro-5-azacytosine ([@b38-mmr-18-05-4446]), SGI-110 (previously known as S110), a dinucleotide of 5-aza-2′-deoxycytidine and deoxyguanosine, containing 5-azaCdR moiety, which has been revealed to be very effective in inhibiting DNA methylation, though its stability and cytotoxicity are comparable to that of decitabine ([@b39-mmr-18-05-4446]), and a non-nucleoside DNA methyltransferase inhibitor, SGI-1027 ([@b40-mmr-18-05-4446],[@b41-mmr-18-05-4446]). To the best of our knowledge, there have been only a few studies investigating the effects of demethylation agents on HCC *in vitro*.

In conclusion, the present study detected genome-wide DNA methylation patterns occurring in Huh7 cells, and identified numerous differentially hypo- and hypermethylated CpG sites, genes, DMRs and signaling pathways associated with HCC. Additionally, the diversity in methylation within Huh7 cells was also observed. The results of the present study may provide important information regarding the molecular mechanisms underlying methylation in Huh7 cells, which may be useful in future research into the underlying mechanisms associated with HCC. In addition, HCC cells may escape or develop tolerance to chemotherapy via various mechanisms, therefore, identifying novel drugs is very important for future therapies of HCC. The application of inhibitors of DNA methylation for the treatment of cancer has gradually attracted more attention within the field ([@b37-mmr-18-05-4446]), and there have been a few studies investigating the effects of demethylation agents in HCC *in vitro*. The results of the present study may provide a useful basis for future research into effective HCC therapies.
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###### 

Distribution of all of the differentially methylated CpG sites.

  Type          All methylated CpG sites, n (%)   Hypermethylated CpG sites, n (%)   Hypomethylation CpG sites, n (%)
  ------------- --------------------------------- ---------------------------------- ----------------------------------
  CpG island    41,178 (40.3)                     19,462 (47.3)                      21,716 (52.7)
  CpG shores    21,150 (20.7)                     13,729 (64.9)                      7,421 (35.1)
  CpG shelves   9,030 (8.8)                       7,340 (81.3)                       1,690 (18.7)
  Open sea      30,896 (30.2)                     22,171 (71.8)                      8,725 (28.2)
  Total         102,254                           62,702                             39,552

###### 

Frequency distribution of all of the differentially methylated CpG sites in Huh7 and L02 cells by methylation status.

  \|β-difference\|, %   Hypermethylated CpG sites, n (%)   Cumulative, %   Hypomethylated CpG sites, n (%)   Cumulative, %   Total CpG sites, n (%)   Cumulative, %
  --------------------- ---------------------------------- --------------- --------------------------------- --------------- ------------------------ ---------------
  ≥60                   25,585 (40.8)                      40.8            10,796 (27.3)                     27.3            36,381 (35.6)            35.6
  50≤x\<60              10,352 (16.5)                      57.3            4,791 (12.1)                      39.4            15,134 (14.8)            50.4
  40≤x\<50              9,681 (15.4)                       72.7            6,159 (15.6)                      54.0            15,840 (15.5)            65.9
  30≤x\<40              8,848 (14.1)                       86.8            8,018 (20.3)                      75.3            16,866 (16.5)            82.4
  20≤x\<30              8,236 (13.1)                       100.0           9,788 (24.7)                      100.0           18,024 (17.6)            100.0
  Total                 62,702                             --              39,552                            --              102,254                  --

###### 

Distribution of genomic regions for significant differentially methylated CpG sites in Huh7 cells when compared with L02 cells.

  Type          Hypermethylated CpG sites, n   Hypomethylated CpG sites, n
  ------------- ------------------------------ -----------------------------
  CpG island    1,544                          1,201
  CpG shores    1,137                            632
  CpG shelves     655                            133
  Open sea      1,949                            693
  Total         5,285                          2,659

###### 

Top 20 significant hypermethylated CpG sites and genes within differentially methylated regions in Huh7 cells when compared with L02 cells.

  CpG sites    Adjust P-value   \|β-difference\|   Mean Huh   Mean L02   Hypermethylated genes
  ------------ ---------------- ------------------ ---------- ---------- -----------------------
  cg11058366   2.09×10^−6^      0.924              0.934      0.010      ERBB4
  cg13245152   1.69×10^−6^      0.863              0.876      0.013      PAX6
  cg25758545   1.69×10^−6^      0.863              0.876      0.013      SALL4
  cg14950829   1.69×10^−6^      0.925              0.940      0.015      PCDH8
  cg09260089   1.69×10^−6^      0.952              0.968      0.016      NKX6-2
  cg11459773   1.69×10^−6^      0.876              0.891      0.015      BCL3
  cg12989574   1.69×10^−6^      0.965              0.983      0.018      GPC6
  cg03129384   1.69×10^−6^      0.956              0.974      0.018      FAM196A; DOCK1
  cg03396151   1.69×10^−6^      0.929              0.947      0.018      MEIS2
  cg04556126   1.69×10^−6^      0.920              0.938      0.018      ZIC4
  cg20317123   1.69×10^−6^      0.947              0.966      0.019      TCF21
  cg21062760   1.69×10^−6^      0.876              0.894      0.018      ZBTB32
  cg09454560   1.99×10^−6^      0.624              0.636      0.013      LRFN2
  cg12090740   1.69×10^−6^      0.892              0.911      0.020      BCL2
  cg24249411   1.69×10^−6^      0.887              0.907      0.020      BDNF
  cg00057722   1.69×10^−6^      0.929              0.950      0.021      --
  cg08640046   1.69×10^−6^      0.810              0.828      0.018      --
  cg03283124   2.03×10^−6^      0.898              0.920      0.021      PCDH9
  cg13087076   1.69×10^−6^      0.890              0.912      0.021      DYDC2
  cg25453154   2.03×10^−6^      0.820              0.839      0.020      ZCCHC24

Data are presented to 3 decimal places.

###### 

Top 20 significant hypomethylated CpG sites and genes within differentially methylated regions in Huh7 cells when compared with L02 cells.

  CpG sites    Adjust P-value   \|β-difference\|   Mean Huh   Mean L02   Hypomethylated gene
  ------------ ---------------- ------------------ ---------- ---------- ---------------------
  cg10739344   1.70×10^−6^      0.894              0.019      0.913      WDR76
  cg00618865   1.69×10^−6^      0.945              0.023      0.967      PLXND1
  cg16267343   1.69×10^−6^      0.898              0.024      0.922      NPR3
  cg00138041   1.69×10^−6^      0.943              0.029      0.972      PRDM8
  cg01529365   1.69×10^−6^      0.930              0.031      0.961      --
  cg09564253   1.69×10^−6^      0.902              0.031      0.933      LASP1
  cg08176368   1.69×10^−6^      0.926              0.033      0.959      MMP9
  cg08812555   2.05×10^−6^      0.784              0.029      0.813      DKK1
  cg25612391   1.77×10^−6^      0.741              0.028      0.769      SLC25A42
  cg22417879   1.70×10^−6^      0.908              0.035      0.943      SDCBP2
  cg15019790   1.69×10^−6^      0.924              0.036      0.960      SIX2
  cg07407787   1.69×10^−6^      0.922              0.036      0.958      ARSG; SLC16A6
  cg08361684   1.69×10^−6^      0.911              0.038      0.949      FJX1
  cg16195157   1.69×10^−6^      0.900              0.038      0.938      DNAJB1
  cg15842502   1.69×10^−6^      0.913              0.040      0.953      RB1
  cg13848566   1.95×10^−6^      0.934              0.041      0.975      GAS1
  cg27454412   1.81×10^−6^      0.781              0.034      0.815      C7orf50
  cg02152578   1.69×10^−6^      0.931              0.041      0.972      AHCYL1
  cg13355248   1.69×10^−6^      0.792              0.038      0.829      NPTX1
  cg16443866   1.69×10^−6^      0.878              0.042      0.920      STC2

Data are presented to 3 decimal places.

###### 

Significant differentially methylated regions.

  DMRs       Significantly hypermethylated sites (n)   Significantly hypermethylated sites (n)
  ---------- ----------------------------------------- -----------------------------------------
  cDMRs        64                                        30
  Island       16                                        4
  Shores       36                                        18
  Shelves      5                                         3
  Open sea     7                                         5
  rDMRs      125                                         74
  Island       38                                        13
  Shores       70                                        50
  Shelves      7                                         3
  Open sea     10                                        8
  DMRs       201                                       104
  Island     179                                         70
  Shores       13                                        21
  Shelves      3                                         0
  Open sea     6                                         13
  Total      390                                       208

DMRs, differentially methylated regions; cDMRs, cancer-specific-DMRs; rDMRs, reprogramming-specific-DMRs.

###### 

Top 20 significant differentially methylated genes in Gene Ontology enrichment.

  GO enrichment                                                   Top 20 significantly hypermethylated genes in GO enrichment                 Top 20 significantly hypomethylated genes in GO enrichment
  --------------------------------------------------------------- --------------------------------------------------------------------------- ------------------------------------------------------------
  Biological process                                                                                                                          
    Positive regulation of protein phosphorylation                ERBB4                                                                       --
    Negative regulation of cell proliferation                     ERBB4                                                                       --
    Epidermal growth factor receptor signaling                    ERBB4                                                                       --
  pathway                                                                                                                                     
    Synaptic transmission                                         PCDH8                                                                       --
    Negative regulation of transcription from RNA                 SALL4; NKX6-2;                                                              --
  polymerase II promoter                                          MEIS2; TCF21; ZBTB32;                                                       
    Fibroblast growth factor receptor signaling pathway           ERBB4                                                                       --
  Molecular function                                                                                                                          
    Protein binding                                               ERBB4; PAX6; BCL3; DOCK1; ZBTB32; BCL2                                      PLXND1; LASP1; MMP9; DKK1; DNAJB1; RB1; GAS1; AHCYL1
    ATP binding                                                   ERBB4                                                                       --
    Sequence-specific DNA binding transcription factor activity   PAX6; NKX6-2; BCL3                                                          SIX2; RB1
    DNA binding                                                   PAX6; SALL4; BCL3; ZIC4; ZBTB32                                             PRDM8; RB1
    Metal ion binding                                             SALL4; ZIC4; ZBTB3                                                          PRDM8; ARSG; NPTX1
    Protein heterodimerization activity                           BCL2                                                                        NPR3; SDCBP2
    Sequence-specific DNA binding                                 BCL2                                                                        SIX2
    Protein kinase binding                                        PAX6                                                                        --
    Transcription regulatory region DNA binding                   ERBB4; TCF21                                                                --
    Protein complex binding                                       --                                                                          SIX2
    Protein dimerization activity                                 TCF21                                                                       --
    Identical protein binding                                     BCL2                                                                        MMP9; RB1
    Protein homodimerization activity                             ERBB4; BCL2                                                                 SDCBP2
    Protein C-terminus binding                                    --                                                                          SDCBP2
  Cellular component                                                                                                                          
    Nucleus                                                       ERBB4; PAX6; SALL4; NKX6-2; BCL3; DOCK1; MEIS2; ZIC4; TCF21; ZBTB32; BCL2   PRDM8; SIX2; RB1
    Cytosol                                                       ERBB4                                                                       --
    Cytoplasm                                                     ERBB4; PAX6; SALL4; BCL3; DOCK1; BCL2; BDNF                                 SDCBP2; DNAJB1
    Nucleoplasm                                                   ERBB4; ZBTB32                                                               RB1
    Golgi apparatus                                               --                                                                          STC2
    Perinuclear region of cytoplasm                               BCL3; BDNF                                                                  NPTX1
    Mitochondrion                                                 ERBB4; BCL2                                                                 SLC25A42
    Nucleolus                                                     ERBB4; PAX6                                                                 DNAJB1; RB1
    Transcription factor complex                                  LRFN2                                                                       --
    Cell junction                                                 PCDH                                                                        --
    Membrane                                                      ERBB4; DOCK1; BCL2                                                          SLC16A6
    Nuclear chromatin                                             PAX6                                                                        --

GO, Gene Ontology.

###### 

Kyoto encyclopedia of genes and genomes pathway analysis of differentially methylated genes.

  Pathway                                       Number of differentially methylated genes (n)
  --------------------------------------------- -----------------------------------------------
  Pathways in cancer                            309
  Focal adhesion                                186
  MAPK signaling pathway                        251
  Wnt signaling pathway                         143
  Axon guidance                                 120
  TGF-β signaling pathway                         81
  Basal cell carcinoma                            55
  Regulation of actin cytoskeleton              191
  Colorectal cancer                               61
  Adherens junction                               71
  Chronic myeloid leukemia                        71
  ECM-receptor interaction                        81
  Endocytosis                                   186
  Pyrimidine metabolism                           97
  Non-small cell lung cancer                      57
  Hedgehog signaling pathway                      54
  Neurotrophin signaling pathway                116
  Glioma                                          63
  Endometrial cancer                              52
  VEGF signaling pathway                          71
  ErbB signaling pathway                          80
  Small cell lung cancer                          80
  Lysosome                                      110
  Metabolic pathways                            964
  Calcium signaling pathway                     159
  Purine metabolism                             150
  Ubiquitin mediated proteolysis                128
  Insulin signaling pathway                     128
  Notch signaling pathway                         45
  Protein processing in endoplasmic reticulum   156
  RNA polymerase                                  32
  Hepatitis C                                   116
  Renal cell carcinoma                            61
  Aminoacyl-tRNA biosynthesis                     42
  B cell receptor signaling pathway               69
  Thyroid cancer                                  29
  Melanoma                                        65
  Oocyte meiosis                                103
  Adipocytokine signaling pathway                 64
  Melanogenesis                                   94
  Vascular smooth muscle contraction            115
  Selenocompound metabolism                       26
  p53 signaling pathway                           63
